Image Credit: Adobe Stock Images/BillionPhotos.com
Done., a provider of hybrid care solutions for attention deficit hyperactivity disorder (ADHD) along with other chronic psychiatric conditions, is boosting its pharmacy network to now involve partnerships with more than 30 pharmacies.1 The various collaborations will help better confirm that medication is accessible for all. Such partnerships aim to ensure that the prescriptions for ADHD medications are filled in a timely manner.
This issue came to light in October 2022, when the FDA first reported Adderall shortages. This affected patients who depend on their medication to manage their ADHD.
The year 2024 represents a time when digital health technology continues to be on the rise. Done., who offers telehealth services, has aimed to further boost its ADHD care through via its online platform. The company also the integrates digital therapies and comprehensive support systems.
“Our approach to ADHD care integrates personalized psychiatry, medication management, and innovative digital health tools,” commented Sussan Nwogwugwu, PMHNP, clinical leader, Done. “This holistic approach ensures that individuals with ADHD receive tailored care that supports their specific health goals and medication to help them manage their conditions.”
Nwogwugwu continued to say that Done. “remains committed to transparency and excellence. Our dedication to maintaining high standards of care is unwavering, and patient welfare is always our top priority.”
In other ADHD news, a study published in Clinical Practice & Epidemiology in Mental Health2 conducted a systemic review of relevant articles to explore the effectiveness of Qbtest—a provider of objective ADHD tests—to monitor medication treatment response. In other words, the goal of the analysis was to examine the works published from 2004 through July 2013 that measure QbTest’s ability to identify changes in test performance as it pertains to the measurement of treatment response when monitoring medication effects in ADHD.
The authors determined that, “a decrease in QbTest Q-scores in the clinical magnitude range was found in the majority of the studies when treated with any type of ADHD medication in therapeutic doses, both in comparison to placebo and compared from baseline to endpoint treatment. This pattern was seen both in short-term (over course of a day) and in long-term (≥ one year) studies. Based on these findings, our conclusion is that QbTest can distinguish medication treatment effects within hours of dosing and can also be used as an aid in the monitoring of long-term treatment of ADHD.”
References
1. Done Global Inc. Unveils Enhanced ADHD Care and Pharmacy Network. PR Newswire. May 9, 2024. Accessed May 10, 2024. https://www.prweb.com/releases/done-global-inc-unveils-enhanced-adhd-care-and-pharmacy-network-302140261.html
2. Saraceno N. Monitoring Response to Attention-Deficit Hyperactivity Disorder Medication. Pharmaceutical Commerce. January 8, 2024. Accessed May 10, 2024. 2. Saraceno N. Monitoring Response to Attention-Deficit Hyperactivity Disorder Medication. Pharmaceutical Commerce. January 8, 2024. Accessed May 10, 2024. https://www.pharmaceuticalcommerce.com/view/monitoring-response-to-attention-deficit-hyperactivity-disorder-medication
